These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 22285449)

  • 1. Axon degeneration in Parkinson's disease.
    Burke RE; O'Malley K
    Exp Neurol; 2013 Aug; 246():72-83. PubMed ID: 22285449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic diversity of axon degenerative mechanisms in models of Parkinson's disease.
    Peters OM; Weiss A; Metterville J; Song L; Logan R; Smith GA; Schwarzschild MA; Mueller C; Brown RH; Freeman M
    Neurobiol Dis; 2021 Jul; 155():105368. PubMed ID: 33892050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies].
    Orimo S
    Rinsho Shinkeigaku; 2008 Jan; 48(1):11-24. PubMed ID: 18386627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson's disease.
    O'Keeffe GW; Sullivan AM
    Parkinsonism Relat Disord; 2018 Nov; 56():9-15. PubMed ID: 29934196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrograde Axonal Degeneration in Parkinson Disease.
    Tagliaferro P; Burke RE
    J Parkinsons Dis; 2016; 6(1):1-15. PubMed ID: 27003783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.
    Orimo S; Uchihara T; Nakamura A; Mori F; Kakita A; Wakabayashi K; Takahashi H
    Brain; 2008 Mar; 131(Pt 3):642-50. PubMed ID: 18079166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the Akt/GSK-3β/CRMP-2 pathway in axon degeneration of dopaminergic neurons resulting from MPP+ toxicity.
    Fang W; Gao G; Zhao H; Xia Y; Guo X; Li N; Li Y; Yang Y; Chen L; Wang Q; Li L
    Brain Res; 2015 Mar; 1602():9-19. PubMed ID: 25150591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Wld(S) mutation delays anterograde, but not retrograde, axonal degeneration of the dopaminergic nigro-striatal pathway in vivo.
    Cheng HC; Burke RE
    J Neurochem; 2010 May; 113(3):683-91. PubMed ID: 20132467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRRK2 and neurodegeneration.
    Santpere G; Ferrer I
    Acta Neuropathol; 2009 Mar; 117(3):227-46. PubMed ID: 19142648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical progression in Parkinson disease and the neurobiology of axons.
    Cheng HC; Ulane CM; Burke RE
    Ann Neurol; 2010 Jun; 67(6):715-25. PubMed ID: 20517933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axon degeneration and PGC-1α-mediated protection in a zebrafish model of α-synuclein toxicity.
    O'Donnell KC; Lulla A; Stahl MC; Wheat ND; Bronstein JM; Sagasti A
    Dis Model Mech; 2014 May; 7(5):571-82. PubMed ID: 24626988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An order in Lewy body disorders: Retrograde degeneration in hyperbranching axons as a fundamental structural template accounting for focal/multifocal Lewy body disease.
    Uchihara T
    Neuropathology; 2017 Apr; 37(2):129-149. PubMed ID: 27862327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease.
    Ren Q; Ma M; Yang J; Nonaka R; Yamaguchi A; Ishikawa KI; Kobayashi K; Murayama S; Hwang SH; Saiki S; Akamatsu W; Hattori N; Hammock BD; Hashimoto K
    Proc Natl Acad Sci U S A; 2018 Jun; 115(25):E5815-E5823. PubMed ID: 29735655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
    Daher JP
    Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell death mechanisms in Parkinson's disease.
    Jellinger KA
    J Neural Transm (Vienna); 2000; 107(1):1-29. PubMed ID: 10809400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson disease: from pathology to molecular disease mechanisms.
    Dexter DT; Jenner P
    Free Radic Biol Med; 2013 Sep; 62():132-144. PubMed ID: 23380027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenges of axon survival: introduction to the special issue on axonal degeneration.
    Coleman MP
    Exp Neurol; 2013 Aug; 246():1-5. PubMed ID: 23769907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.